BNP Paribas Financial Markets Grows Stock Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

BNP Paribas Financial Markets increased its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 24.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,442 shares of the company’s stock after purchasing an additional 21,012 shares during the period. BNP Paribas Financial Markets owned approximately 0.26% of SI-BONE worth $1,488,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SIBN. FMR LLC lifted its holdings in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after buying an additional 1,198 shares during the period. Canada Pension Plan Investment Board acquired a new position in SI-BONE in the second quarter valued at approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after purchasing an additional 2,108 shares in the last quarter. Arizona State Retirement System grew its stake in shares of SI-BONE by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after purchasing an additional 903 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new position in shares of SI-BONE during the 2nd quarter valued at approximately $151,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at SI-BONE

In related news, CEO Laura Francis sold 10,048 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.58, for a total transaction of $126,403.84. Following the transaction, the chief executive officer now directly owns 482,875 shares in the company, valued at approximately $6,074,567.50. The trade was a 2.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Anshul Maheshwari sold 2,439 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.68, for a total transaction of $30,926.52. Following the completion of the sale, the chief financial officer now owns 194,623 shares of the company’s stock, valued at approximately $2,467,819.64. The trade was a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,679 shares of company stock valued at $276,439 over the last quarter. 3.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

SIBN has been the topic of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of SI-BONE in a research report on Wednesday, November 20th. Truist Financial raised their target price on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $23.00.

SI-BONE Stock Up 0.9 %

SIBN opened at $13.52 on Monday. The company has a market cap of $567.00 million, a PE ratio of -14.70 and a beta of 1.20. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $21.70. The company has a 50-day moving average price of $13.41 and a 200 day moving average price of $14.09. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.